'Buyer Beware?'

The Motley Fool's Brian Orelli this week calls genome sequencing "the world's best innovation that isn't worth investing in." Orelli says that he sees "little reason to invest in the genome sequencing industry," particularly because "what's great for the end users isn't necessarily great for those producing the tools."

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.

Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.

Researchers in the UK are working on using gene drives to control malaria-carrying mosquitoes, the Telegraph reports.

In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.